Glucose transporter type 10-lacking in arterial tortuosity syndrome-facilitates dehydroascorbic acid transport by Németh, Csilla E. et al.
Glucose transporter type 10—lacking in arterial tortuosity
syndrome—facilitates dehydroascorbic acid transport
Csilla E. Nemeth1, Paola Marcolongo2, Alessandra Gamberucci2, Rosella Fulceri2,
Angiolo Benedetti2, Nicoletta Zoppi3, Marco Ritelli3, Nicola Chiarelli3, Marina Colombi3, Andy
Willaert4, Bert L. Callewaert4, Paul J. Coucke4, Pal Grof5, Szilvia K. Nagy1, Tamas Meszaros1,
Gabor Banhegyi1 and Eva Margittai6
1 Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest, Hungary
2 Department of Molecular and Developmental Medicine, University of Siena, Italy
3 Division of Biology and Genetics, Department of Molecular and Translational Medicine, Medical Faculty, University of Brescia, Italy
4 Center for Medical Genetics, Ghent University, Belgium
5 Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
6 Institute of Clinical Experimental Research, Semmelweis University, Budapest, Hungary
Correspondence
E. Margittai, Institute of Clinical
Experimental Research, Semmelweis
University, 1094 T}uzolto utca 37-47,
Budapest, Hungary
Fax/Tel: +36 1 2662615
E-mail: margittai.eva@med.semmelweis-
univ.hu
(Received 3 March 2016, revised 20 April
2016, accepted 3 May 2016, available online
27 May 2016)
doi:10.1002/1873-3468.12204
Edited by Lukas Alfons Huber
Loss-of-function mutations in the gene encoding GLUT10 are responsible for
arterial tortuosity syndrome (ATS), a rare connective tissue disorder. In this
study GLUT10-mediated dehydroascorbic acid (DAA) transport was investi-
gated, supposing its involvement in the pathomechanism. GLUT10 protein
produced by in vitro translation and incorporated into liposomes efficiently
transported DAA. Silencing of GLUT10 decreased DAA transport in immor-
talized human fibroblasts whose plasma membrane was selectively permeabi-
lized. Similarly, the transport of DAA through endomembranes was markedly
reduced in fibroblasts from ATS patients. Re-expression of GLUT10 in
patients’ fibroblasts restored DAA transport activity. The present results
demonstrate that GLUT10 is a DAA transporter and DAA transport is
diminished in the endomembranes of fibroblasts from ATS patients.
Keywords: arterial tortuosity syndrome; ascorbate; dehydroascorbic acid;
endomembranes; Fe2+/2-oxoglutarate-dependent dehydrogenases; GLUT10
The Major Facilitator Superfamily consists several
thousands of membrane transporters, including the
SLC2A (solute carrier 2A) gene family encoding glu-
cose transporter (GLUT) proteins. GLUT family
members—presently 14 proteins—are grouped into
three different classes based on their sequence similari-
ties; GLUT10 encoded by SLC2A10 gene belongs to
class 3 [1]. Loss-of-function mutations in the SLC2A10
gene are responsible for arterial tortuosity syndrome
(ATS); however, the precise cellular location, the
transported ligand(s), and the exact physiological role
of GLUT10 have not been clarified.
Arterial tortuosity syndrome (OMIM #208050) is a
monogenic autosomal recessive heritable connective tis-
sue disorder characterized by elongation and general-
ized tortuosity of the major arteries. The clinical
phenotype also includes aneurysms of large arteries and
stenosis of the pulmonary artery. Patients usually pre-
sent dysmorphic facial features and other connective tis-
sue abnormalities such as hyperextensible skin and joint
laxity [2–5]. Histopathological analysis shows extreme
disorganization and fragmentation of elastic fibers in
the arterial wall [2]. SLC2A10 has been localized to
human chromosome 20q12–q13.1, one of the genomic
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loci associated with noninsulin-dependent diabetes mel-
litus (NIDDM), thus SLC2A10 has previously been
considered as a candidate gene for NIDDM [6]. How-
ever, independent studies have failed in confirming any
association between SLC2A10 mutations and NIDDM
[7–9]. Three mechanisms have been proposed to explain
the link between defective GLUT10 activity and the
arterial defects described in ATS.
The first hypothesis, based on the perinuclear local-
ization of GLUT10 in human fibroblasts, assumes that
the glucose-dependent regulation of gene expression is
altered in ATS. In particular, since in ATS cells the
expression of decorin, a known proteoglycan TGFb
signaling inhibitor, was found down-regulated [2], it
was supposed that the glucose-induced upregulation of
decorin is missing in ATS, also explaining the upregu-
lation of the TGFb pathway observed in ATS cells [2].
The second theory suggests that GLUT10 is involved
in the transport of dehydroascorbic acid (DAA), the
oxidized form of the potent antioxidant ascorbic acid
(AA) across the mitochondrial membranes, where
GLUT10 has been localized with immunofluorescence
studies in smooth muscle cells and adipocytes [10].
Upon being transported into mitochondrial matrix,
DAA is reduced to AA, which can eliminate reactive
oxygen species (ROS), thereby protecting the cell from
oxidative stress. The ROS levels in the aortic smooth
muscle cells of GLUT10 knockout mice [10] are indeed
higher under oxidative stress conditions and their mito-
chondrial DAA transport activity is reduced. However,
the relevance of these findings can be questioned as the
phenotype of the GLUT10 knockout mice is very mild
[11] or even normal [12] as compared to the human
ATS phenotype.
A third hypothesis, based on our previous works
[13–15] has also been proposed [16]. According to this
hypothesis, GLUT10 acts as a DAA transporter in the
endoplasmic reticulum (ER) membrane. DAA, in turn,
is reduced to AA in the ER lumen, where it acts as a
cofactor for the hydroxylation of prolyl and lysyl resi-
dues by Fe2+/2-oxoglutarate-dependent dioxygenases,
a biochemical reaction crucial for collagen and elastin
maturation and folding. Supporting the hypothesis, it
was shown that transiently transfected GLUT10-GFP
constructs and organelle-specific fluorescent probe ER-
Tracker Blue-White colocalized in rat aortic smooth
muscle cells [16]. However, transport activities have
not been demonstrated in the ER and other subcellular
compartments.
As we demonstrated earlier, DAA is imported into
the microsomal lumen by a transport system sharing the
inhibitory properties of GLUTs [13] and DAA-derived
AA accumulates in the ER lumen [14,15,17].
The transport activity was present not only in liver
microsomes [13] but also in microsomes from various
nonhepatic tissues/cells, including human fibroblasts
[15].
Up to now, glucose or DAA transporters have not
been molecularly characterized in the endomembranes.
The presence of a glucose transporter has long been
supposed as a component of the glucose-6-phosphatase
system of the ER [18]. This assumption was experi-
mentally confirmed using genetically encoded fluores-
cence resonance energy transfer nanosensors [19].
Glucose transport was shown to be mediated by at
least two transporters with different characteristics in
rat liver microsomes [20]. A possible explanation for
this heterogeneity is that various plasma membrane
GLUT transporters function locally during ER-to-
plasma membrane transit [21]. Transport of DAA is
typically mediated by GLUT transporters both in the
plasma membrane and endomembranes [22]. There-
fore, DAA transport in the ER can be also mediated
by a GLUT transporter.
To date, there is no consensus regarding the subcel-
lular localization of GLUT10 and the ligand it trans-
ports. On the other hand, GLUT10 could excellently
act the part of the missing glucose/DAA transporter
of the ER. Therefore, the aim of this study was to ver-
ify the role of GLUT10 as a DAA transporter. Our
observations demonstrate that GLUT10 is functioning
as a DAA transporter and DAA transport activity is
diminished in the endomembranes of fibroblasts from
ATS patients lacking functional GLUT10 transporter.
Materials and methods
Patients and cell cultures
Skin fibroblasts from ATS patients and unrelated healthy
donors were established from skin biopsies as previously
reported [2]. Patient 1 (P1) was homozygous for the
c.1334delG microdeletion [2]; patient 2 (P2) was compound
heterozygous for the c.1309G>A and the c.1330C>T transi-
tions [23]; patient 3 (P3) was homozygous for the
c.1411+1G>A splicing mutation [24]; and patients 4–8 (P4–
P8), members of the same family, all bearing the homozy-
gous c.510G>A mutation [2]. Written informed consent was
obtained from each patient for skin biopsy procedure. This
study was approved by the medical ethical committee of
the University Hospital Spedali Civili of Brescia, Italy (in
case of P1–P3) and by the Ghent University Hospital, Bel-
gium (for P4–P8), and was performed in accordance with
the Declaration of Helsinki Principles.
Dermal fibroblasts cultures were grown in vitro at 37 °C
in a 5% CO2 atmosphere in Earle’s Modified Eagle Med-
ium (MEM) supplemented with 2 mM L-glutamine, 10%
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FBS, 100 lg/mL penicillin and streptomycin (Life Tech-
nologies, Carlsbad, CA, USA). Cells were analyzed at the
same in vitro passage number (5th to 7th).
Construction of a stable GLUT10 expression
vector
A stable GLUT10 expression vector was generated as pre-
viously reported [25]. Briefly, the full length of human
SLC2A10 cds (refseq: NM_030777.3) was amplified from
total RNA of normal skin fibroblasts with the SuperScript
III One-Step RT-PCR System and inserted into the eukary-
otic pEF6/V5-His-TOPOTM expression vector containing the
blasticidin-selectable marker gene and the strong human
elongation factor 1a promoter (Life Technologies). This
expression vector (pG10) and the empty cloning vector
(mock) were stably transfected in the skin fibroblasts of P1
using the FUGENE 6 liposomal transfection reagent
(Roche Applied Science, Mannheim, Germany). Selection
was achieved by adding selective medium (2 lg/mL of blas-
ticidine) that was changed every 3 days until the elimina-
tion of all sensitive cells. Established cell lines carrying an
integrated pG10 construct or empty vector were expanded
for subsequent experiments.
Indirect immunofluorescence analysis
To analyze the presence and distribution of GLUT10, con-
trol, untransfected and mock-transfected ATS fibroblasts,
and ATS cells re-expressing GLUT10 were grown for 48 h
and reacted for 2 min with 3% paraformaldehyde/0.5%
Triton, 20 min with 3% paraformaldehyde, washed with
100 mM glycine/PBS, blocked for 30 min with 5% BSA,
and immunoreacted overnight at 4 °C with 20 lg/mL poly-
clonal rabbit anti-GLUT10 antibody (Alpha Diagnostic
Int. Inc., San Antonio, TX, USA). After washing in PBS,
cells were incubated for 1 h at room temperature with the
rhodamine-conjugated anti-rabbit secondary antibody. The
signals were acquired by a CCD black and white TV cam-
era (SensiCam-PCO Computer Optics GmbH, Kelheim,
Germany) mounted on a Zeiss fluorescence Axiovert micro-
scope, and digitalized by Image Pro Plus program (Media
Cybernetics, Silver Spring, MD, USA). The experiments
were repeated three times.
Subcellular fractionation of human fibroblasts
Microsomal fraction was prepared from human fibroblasts
as reported earlier [26] with minor modifications. The tryp-
sinized cells were resuspended in sucrose-HEPES buffer
(0.34 M sucrose, 10 mM HEPES; pH 7.4) and sonicated five
times for 15 s at 4 °C using Sonic 300 Dismembrator (35%
pulse cycle). Cell homogenates were centrifuged for 10 min
at 1000 g. The postnuclear supernatant were centrifuged
for 20 min at 18 000 g. Microsomes were recovered by
ultracentrifugation for 60 min at 195 000 g. Pellets were
resuspended in 20 mM MOPS buffer (pH 7.2) and main-
tained in liquid N2.
hTERT fibroblast cultures
BJ-5ta hTERT immortalized fibroblasts from LGC Stan-
dards (Teddington, Middlesex, UK) were cultured in a
4 : 1 mixture of Dulbecco’s Modified Eagle Medium (Life
Technologies) and Medium199 (Life Technologies)
supplemented with 0.01 mg/mL hygromycin B (Life
Technologies), 10% FBS (Life Technologies) and 1%
Antibiotic–Antimycotic (Life Technologies). All cultures
were grown in 75-cm2 cell culture flasks (Sigma-Aldrich
Co., Saint Louis, MO, USA) and maintained in a humidi-
fied incubator at 37 °C with a 5% CO2 in air atmosphere.
Silencing
shRNA-mediated knockdown of the SLC2A10 gene was
achieved with human GIPZ lentiviral shRNAmir constructs
containing viral particles (Costume-made by Thermo Fisher
Scientific Rockford, IL, USA). Three different silencing
sequences and a scrambled sequence were cloned in lentivi-
ral vectors to produce viral particles. Infection of hTERT
cells was performed according to the manufacturers’
instructions (Thermo Fisher Scientific—Technical Manual
—Expression Arrest GIPZ Lentiviral shRNAmir), with a
multiplicity of infection (MOI) of 3 : 1. For stable expres-
sion experiments, selection of transduced cells was per-
formed with puromycin, starting 48 h after infection.
RNA isolation and PCR analysis
RNA was isolated using the RNeasy Plus Mini Kit (Qia-
gen, Venlo, the Netherlands) according to the manufac-
turer’s instructions. Two micrograms of RNA were reverse
transcribed with SuperScript III First-Strand Synthesis
System for RT-PCR (Thermo Fisher Scientific) and ran-
dom hexamers. Expression levels of SLC2A10 were quanti-
fied by fluorescent real-time PCR with a DNA engine
thermal cycler (MJ Research, Waltham, MA, USA)
equipped with Opticon Monitor 4 software. Analyses were
performed in triplicates in a 25-lL reaction mixture. cDNA
(1 lL) was amplified with Platinum SYBR Green qPCR
SuperMix UDG (Invitrogen) and 200 nM of the sense and
antisense primers. For SLC2A10, the oligonucleotide pri-
mers were: sense, 50 CTTCAACTGGGCGGCCAACCT30;
antisense, 50 CGAGGACAGCGGTCAGTCCGT30. Ampli-
fication protocol was: 95 °C (10 min), 40 cycles of 95 °C
(20 s), 55 °C (20 s), 72 °C (20 s). The PCR amplification effi-
ciency was evaluated by serial (10- fold) dilutions of the
human cellular cDNA. Diluted and undiluted samples were
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then analyzed in duplicate. Amplification efficiency was cal-
culated as reported [27]. The amplification efficiency was
more than 90%. Every assay was run in triplicate and nega-
tive controls (no template, template produced with no
reverse transcriptase enzyme) were always included. In the
negative controls, no signal was detected in the investigated
amplification range (40 cycles).
Western blot analysis
For western blot analysis, hTERT cells were subcultured in
a 6-well plate, and used after 2–3 days. Confluent wells
were washed with PBS and lysed with RIPA buffer (50 mM
Tris-Cl, pH8, 150 mM NaCl, 1% NP40, 0.1% SDS). Total
protein concentration was determined by Pierce BCA Pro-
tein Assay Kit (Thermo Fisher Scientific). Equal protein
amounts (15–20 lg) were subjected to 10–12% SDS/PAGE
and transferred to polyvinylidene difluoride membranes by
semidry western blotting. The membranes were blocked in
5% milk or 5% BSA overnight, then probed using specific
rabbit polyclonal anti-glucose transporter GLUT10 anti-
body (1 : 1000; Abcam, Cambridge, UK) and GAPDH
(1 : 7500; Santa Cruz Biotechnology, Inc., Dallas, TX,
USA). The western blots were developed using chemilumi-
nescent detection system (Thermo Fisher Scientific). Protein
levels were evaluated through densitometry.
Preparation of cells for transport measurements
Cells grown in 75-cm2 cell culture flasks, were detached by
trypsinization, harvested by centrifugation (5 min; 600 g),
washed, recentrifuged, and resuspended in sterile PBS
(2 9 106 cells/mL).
Plasma membrane-permeabilized fibroblasts were pre-
pared as described above, except that following the last
centrifugation step cells were resuspended in MOPS buffer
(100 mM KCl, 20 mM NaCl, 1 mM MgCl2, 20 mM MOPS,
pH 7.2). Having counted the cells, suspensions were incu-
bated at 4 °C in the presence of 1 mM NaN3 and 40 lM
digitonin until permeabilized (10–20 mins). Plasma mem-
brane permeabilization was controlled by trypan blue
exclusion. After removal of digitonin by centrifugation,
cells were used for transport assays.
Liposome preparation
Large unilamellar liposomes (LUV) were prepared from L-
a-phosphatidylcholine from egg yolk (egg-lecithin, Cat. No.
61755; Sigma-Aldrich Co.). Appropriate amount of lipids,
dissolved in chloroform-methanol (9 : 1) mixture, was dried
as a thin film on the wall of a glass tube under argon
stream and the traces of the organic solvents were further
removed in a vacuum desiccator at 2 Hg mm for 30 min.
Multilamellar liposomes were prepared at 40 °C in 20 mM
Hepes buffer (pH 7.5) supplemented with 10 mM GSH in a
lipid concentration of 20 mg/mL. LUV were obtained by
extrusion of the multilamellar vesicle suspension through a
polycarbonate filter (pore size 0.4 lm, Nuclepore Track-
Etch Membrane; Whatman International Ltd.; Maidstone,
Kent, UK). At least 40 extrusion cycles were performed at
40 °C (the extruder and the filters were purchased from
Avanti Polar Lipids Inc. Alabaster, Alabama USA). Prote-
oliposomes were prepared from and transport experiments
were performed on freshly prepared LUVs. For the
preparation of proteoliposomes, 5 lL of liposomes (20 mg
L-a-phosphatidylcholine/mL) was fused with 10 lg of
in vitro-translated GLUT10 protein or 60 lg of microsomal
protein.
In vitro translation of GLUT10 transporter
Human SLC2A10 gene was amplified from GLUT10 vector
(pLenti-suCMV-hSLC2A10, Rsv RFP-Puro, 150 ng/lL,
Amsbio) by PCR using primers 50TACTTCCAATCCAAT
GCAATGGGCCACTCCCCACCT30 and 50TTATCCACT
TCCAATGCATCAGGAGGCCGCAGAGAT30. The PCR
product was transferred into pEU3-NII-GLICNot vector
by ligation-independent cloning. The vector construct is a
modification of wheat germ translation vector [28] and
codes the recombinant protein with TEV protease cleavable
GST affinity tag. Escherichia coli-competent cells were
transformed with these GLUT10 possessing vectors. Plas-
mid purified from ampicillin-resistant colony was sequenced
to confirm the PCR accuracy.
The in vitro mRNA synthesis was accomplished by the
addition of 1 lg of purified, NotI-linearized vector follow-
ing the provided manual of the kit (TranscriptAid T7 High
Yield Transcription Kit; Thermo Fisher Scientific). The
reaction was incubated for 2 h at 37 °C and then precipi-
tated by ammonium acetate/ethanol mixture. The mRNA
pellet was washed with absolute ethanol, air-dried, and dis-
solved in SUB-AMIX buffer of cell-free translation.
The batch-wise translation mixture contained 5 lL wheat
germ extract (Cell Free Sciences), 1 lg mRNA, 5 lL lipo-
some (20 mg/mL), 0.8 lL creatine kinase (1 mg/mL), and
was completed to 25 lL final volume with 19 SUB-AMIX
solution [29]. The reaction was incubated at room tempera-
ture for 3 h. The control reactions were set up either without
liposome or exogenous mRNA. The reaction mixtures were
centrifuged at 10 000 g for 30 min and both the supernatant
and the pellet were analyzed by western blot. It was observed
that the presence of liposomes resulted in more effective
translation and less aggregation of GLUT10 protein.
Transport assays
The uptake/transport of DAA, AA, and other compounds
was investigated by a rapid filtration method with trace
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amount of radiolabeled compounds as described previ-
ously [13]. Intact and plasma membrane-permeabilized
cells incubated in the presence of the indicated ligands
and their radiolabeled analogs for the indicated times were
filtered through glass fiber paper GF/C; 2.5 cm; pore size
0.45 lm (Whatman International Ltd.). Filters were
washed with 2 mL of the medium and the radioactivity
retained on the filter was measured by liquid scintillation
counting. In each experiment, deoxycholate (0.4% final
concentration) was added at the end of the incubations;
the radioactivity not released by this maneuver was
regarded as binding and was subtracted from the mea-
sured values.
Transport into microsomes and proteoliposomes was
measured by the same method as described in details earlier
[13]. Since the yield of microsomal fraction was poor from
fibroblasts, microsomal vesicles were fused with liposomes
and transport assays were performed on the resulting chi-
meric vesicles.
The following radiolabeled compounds were used in the
experiments: D-[U-14C]Glucose; (Cat. No.: CFB2); Amer-
sham Biosciences UK Ltd.; Little Chalfont, Bucking-
hamshire, UK; [U-14C]Sucrose; (Cat. No.: CFB146);
Amersham Biosciences UK Ltd.; Uridine Diphosphate Glu-
curonic Acid, [Glucuronyl-U-14C]; (Product No.:
NEC414010UC) Perkin Elmer; Boston, MA, USA; Ascor-
bic Acid, L-[1-14C]; (Cat. No.: ARC1569); American Radi-
olabeled Chemicals, Inc.; 101 ARC Drive, Saint Louis,
MO, USA. DAA was prepared by the bromine oxidation
method as reporter earlier [13].
Measurement of AA/DAA by HPLC
Intra- and extracellular total vitamin C levels (AA + DAA)
were determined by HPLC [30]. Cells were incubated in the
presence of 50 lM AA for 0, 6, 12, 24 h. After incubation,
the cells were washed twice with PBS and scraped with rub-
ber policeman in 25 w/v% metaphosphoric acid solution.
To measure AA and DAA together, 5 mM DTT (final con-
centration) was added to the samples and they were incu-
bated for 20 min at room temperature. Before HPLC
measurement, samples were centrifuged at 3000 g for
10 min. Vitamin C was measured from the clear super-
natant. Samples were eluated through the column (Teknok-
roma NUCLEOSIL 100 C18 5 lm, 25 9 0.46 mm) with
0.1 M Sodium-Dihydrogene-Phosphate solution (pH 3.1)
containing 0.2 mM EDTA. Vitamin C content of the med-
ium was determined using the same method.
Results
GLUT10 is a DAA transporter
In the first set of experiments, DAA transport was
measured in GLUT10-containing proteoliposomes.
GLUT10 protein was produced in an in vitro
Fig. 1. GLUT10 protein acts as a DAA/glucose transporter in proteoliposomes. (A) GLUT10 protein was produced by an in vitro translation
method and was incorporated into liposomes. Transport activities were measured by a rapid filtration method and radiolabelled ligands. The
following ligands were used (in 1 mM concentration if not indicated otherwise): DAA (○); DAA 5 mM (●); AA (M); glucose (▼); UDP-
glucuronic acid (Ⓧ); sucrose (□). Transport of protein-free liposomes with 1 mM DAA was also measured (♢). (B) DAA transport (1 mM) was
measured in proteoliposomes gained by the fusion of microsomes prepared from the fibroblasts of healthy controls (○) and ATS patients P4
and P7 (●) with liposomes. Results are expressed as means  SEM of four experiments or (where SEM bars are missing) as means of
two measurements.
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translational system and the protein was incorporated
into liposomes to exclude the eventual indirect effects
of the lack of GLUT10 on DAA transport. The pres-
ence of GLUT10 in the proteoliposomes was checked
by immunoblotting (data not shown). GLUT10-con-
taining proteoliposomes efficiently transported DAA
in a concentration-dependent way (Fig. 1A). Glucose
transport was also measurable, while unrelated com-
pounds such as UDP-glucuronic acid and sucrose were
not transported. A very low AA uptake was also
observed, which was presumably due to the oxidation
of AA to DAA during the incubation [14]. Incorpora-
tion of microsomal proteins prepared from human
control fibroblasts into liposomes also promoted the
transport of DAA (Fig. 1B). Protein-free liposomes
did not show transport activities (Fig. 1A).
Silencing of GLUT10 compromises DAA transport
To demonstrate the involvement of GLUT10 in subcel-
lular DAA transport, a hTERT immortalized human
fibroblast cell line was silenced for GLUT10 with
lentiviral-based silencing vectors. Stable clones express-
ing the silencing vector were selected and were checked
for the efficiency of silencing. Semiquantitative RT-
PCR analysis of the stable clones showed that two
silencing constructs out of three were effective
(Fig. 2A).
Immunoblotting of cell homogenates revealed that
only one of the constructs decreased GLUT10 at protein
level effectively (Fig. 2B). Measurement of DAA trans-
port on plasma membrane-permeabilized hTERT
immortalized human fibroblasts showed that it was
severely decreased in these efficiently silenced cells
(Fig. 2C). Strict correlation (R2 values between 0.8859
and 0.9967) was observed when DAA transport activities
were plotted against GLUT10 protein levels detected by
western blot in silenced fibroblasts (Fig. 2D).
DAA transport through endomembranes is
defective in ATS
The uptake of DAA and its reduced form, AA, was
investigated in intact human fibroblasts from healthy
55 kDa
40 kDa
GLUT10
GAPDH
B
D
C
**
**
*
**
**
*
*
A
Fig. 2. Silencing of GLUT10 in hTERT-
immortalized human fibroblasts decreases
DAA transport through the
endomembranes. Silencing of GLUT10 in
human hTERT fibroblasts were executed
with lentiviral-based silencing vectors
expressing three different shRNA
sequences. Out of the three constructs,
two (shRNAII and shRNAIII) were proven
to be effective in silencing the transporter
with RT-PCR analyses (A). Effective
silencing was also verified by
immunoblotting at protein level (B). Right
panel shows one representative western
blot out of four; the result of densitometric
analysis is presented on the left panel.
GAPDH is used as housekeeping marker.
Examination of DAA uptake (1 mM) in
mock silenced and effectively silenced cell
lines was performed with rapid filtration
technique (C). DAA transport significantly
decreased in both cell lines that were
effectively silenced. Results are expressed
as means  SEM of 5–10 experiments.
Correlation between GLUT10 protein
levels and DAA transport activities in mock
silenced and effectively silenced cell lines
is shown in (D). Data are taken from
panels B and C. Asterisks mark
statistically significant differences from
mock transfected (*P < 0.05; **P < 0.01).
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controls and ATS patients. Decreased DAA (Fig. 3A)
and unchanged AA transport (Fig. 3B) was observed
in the patients’ fibroblasts, indicating a DAA-specific
failure of vitamin C transport. Investigation of long-
term AA uptake and accumulation in the presence of
physiological AA concentration (50 lM) revealed that
the steady-state intracellular concentration of AA was
set up at a lower level in patients’ fibroblasts compar-
ing with the controls (Fig. 3C).
To estimate the transport through endomembranes,
the plasma membrane of the cells was selectively per-
meabilized. An even more dramatic decrease in DAA
transport was found in cells from ATS patients under
this condition, which indicated that the failure is due
to a transporter resident in the endomembranes
(Fig. 3D). AA transport was similar in permeabilized
control and patient fibroblasts (Fig. 3E).
Re-expression of GLUT10 in ATS fibroblasts
restores DAA transport
GLUT10 expression vector (pG10) and empty cloning
vector (mock) were stably transfected in the skin
fibroblasts of an ATS patient (P1). P1 was intention-
ally used in the re-expression experiments to avoid any
interference with an eventual mutated protein present
in the ATS fibroblasts, because of the almost complete
lack of GLUT10 mRNA, due to the activation of
Fig. 3. DAA transport through
endomembranes is defective in ATS. DAA
(A) and AA (B) uptake was measured in
intact control (empty circles) and ATS
fibroblasts (black circles) using a rapid
filtration method and radiolabeled ligands
(1–1 mM). Panel C shows the long-term
uptake of 50 lM AA in fibroblasts,
measured by HPLC. DAA (D) and AA (E)
uptake (1–1 mM) was also measured in
plasma membrane-permeabilized control
and ATS fibroblasts using the rapid
filtration method and radiolabeled ligands
(1–1 mM). Fibroblasts from P1, P3, P4, P5,
P7, and P8 (panels A, B, D, E) or from P3,
P4, P7, and P8 (panel C) were used.
Results are expressed as means  SEM
of 6–10 experiments or (where SEM bars
are missing) as means of two
measurements.
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nonsense-mediated mRNA decay. These transfected
cells do not only re-express GLUT10 but also rescue a
control-like phenotype concerning the extracellular
matrix homeostasis and GLUT10-dependent canonical
signal transduction mechanisms, as shown in [25]. The
absence of the immunoreactivity of GLUT10 was
observed in nontransfected (Fig. 4B) and mock-trans-
fected (Fig. 4C) cells. Re-expression of GLUT10 in
patients’ fibroblasts resulted in the appearance of
GLUT10 immunoreactivity as revealed by immuno-
cytofluorescence (Fig. 4D; for comparison see control
fibroblasts, Fig. 4A). Re-expression also restored the
impaired DAA transport activity in plasma mem-
brane-permeabilized cells (Fig. 4E).
Discussion
Although mutations in the SLC2A10 gene encoding
the GLUT10 protein have been unequivocally identi-
fied as the genetic cause of ATS, the underlying patho-
genetic mechanisms have not been elucidated up to
now. The determination of the intracellular localiza-
tion of GLUT10 and the identification of the ligand(s)
it transports are crucial for further clarifying the role
of GLUT10 in cardiovascular development. The
results that we obtained demonstrate that GLUT10 is
a DAA transporter, and DAA transport is defective
through the endomembranes of ATS fibroblasts.
We demonstrated, by incorporating in vitro-trans-
lated GLUT10 protein into liposomes, that it acts as a
specific DAA/glucose transporter. Incorporation of
microsomal proteins from control and ATS fibroblasts
into liposomes showed that DAA transport was
reduced in proteoliposomes containing patients’ micro-
somal proteins. In plasma membrane-permeabilized
cells a huge decrease in DAA transport of ATS
patients’ skin fibroblasts was observed, indicating the
defect of DAA transport through the endomembranes.
The deficient transport was restored by the re-expres-
sion of GLUT10 in ATS fibroblasts. Moreover, silenc-
ing of GLUT10 in hTERT fibroblasts also
compromised DAA transport through the endomem-
branes.
The finding that GLUT10 acts as a DAA trans-
porter is supported by some previous observations.
The human phenotype of ATS could not be repro-
duced in GLUT10 mutant mice, as these mice showed
minimal or no pathological signs [11,12]. The absence
of a relevant phenotype in mice could be explained by
the fact that mice, in contrast to humans, possess
gulonolactone oxidase activity. Thus, mice are able to
synthesize AA, independently of dietary intake.
A
B
C
D
E
Fig. 4. Expression of GLUT10 in ATS fibroblasts restores DAA transport. Stable transfection of GLUT10 into the fibroblasts of the ATS
patient P1 resulted in the appearance of GLUT10 protein in the cells, as it was verified by immunocytochemistry. A, control fibroblasts; B,
ATS fibroblasts; C, ATS fibroblasts, mock transfected; D: pG10-transfected ATS fibroblasts. DAA (1 mM) transport activity could be
measured in plasma membrane permeabilized, GLUT10 re-expressing cells (panel E; empty circles, means  SEM of three experiments). In
panel E, the DAA uptake in permeabilized ATS fibroblasts, shown in Fig. 3D, is also reported for comparison (black circles).
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It may be hypothesized that in AA-synthesizing spe-
cies an enhanced AA production can compensate
somehow for the reduced activity of organellar AA/
DAA transporters. This hypothesis is reinforced by the
relevant cardiovascular abnormalities that have been
identified in a zebrafish ATS model [31]. This and
other teleost species, like humans, lack a functional
gulonolactone oxidase gene.
A glucose transporter in the endomembranes, espe-
cially in the ER has long been hypothesized as a com-
ponent of the ER-localized glucose-6-phosphatase
system [18]. The presence of GLUT10 in the
endomembranes as a DAA and glucose transporter
can be the molecular background of the functionally
already observed transport activities [19,20,32]. How-
ever, it is probable that GLUT10 is not a single DAA/
glucose transporter in the endomembranes. Functional
studies indicated the heterogeneity of glucose transport
in the ER [19,20]. Moreover, it was also demonstrated
that various GLUT transporters can sufficiently medi-
ate glucose transport en route from the ER to the
plasma membrane [21]. These circumstances may pro-
vide an explanation for the fact that GLUT10 defi-
ciency does not affect similarly all cell types.
The question arises: which function of DAA/AA is
missing in the secretory compartment and/or nucleo-
plasm in ATS patients? Besides the general antioxidant
role, AA acts also as a cofactor for 2-oxoglutarate/
Fe2+-dependent dioxygenases [33]. Prolyl- and
lysyl-hydroxylases involved in the post-translational
modification of collagen and other extracellular matrix
proteins such as elastin belong to this group of the
enzymes [34] as many nucleoplasmic DNA and histone
demethylases [35]. DAA has been nominated as an
electron acceptor in the process of oxidative protein
folding, that is, in the formation of disulfide bonds
[15,36]. Thus, shortage of AA in the nucleoplasm and
in the lumenal compartments of the secretory pathway
can depress the production of extracellular matrix pro-
teins at both epigenetic and post-translational levels
[22]. Indeed, changes of gene expression has been
demonstrated by a recently published transcriptome
analyses in ATS fibroblasts. The alterations affected
the expression of several genes involved not only in
TGFb signaling and extracellular matrix organization
and homeostasis but also in specific pathways that
control cell energy balance and the oxidative stress
response [25]. Although further studies are needed to
clarify the role of these changes in the pathogenesis of
ATS, the results presented here clearly show that
GLUT10 can mediate the membrane transport of
DAA and this transport is defective in the endomem-
branes of ATS fibroblasts.
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